Filing Details
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) filed a Form 8-K with the Securities and Exchange Commission on August 10, 2026, disclosing a material event.
8k filedNASDAQ:FULC
Fulcrum Therapeutics, Inc. (FULC) Reports Material Event to SEC
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) filed a Form 8-K with the Securities and Exchange Commission on August 10, 2026, disclosing a material event.
At publication ·
What changed
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) · 8k filed
- Form
- 8-K
At a glance
Key takeaways
- Fulcrum Therapeutics filed a Form 8-K with the SEC on August 10, 2026, disclosing a material event that shareholders should be aware of, though the specific nature of the event is not detailed in this article.
- The company's stock trades at $3.75 with a market capitalization of $692.6 million as of the filing date.
- Material events reported on Form 8-K can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance, and investors can access full details through the SEC's EDGAR database.
Market Context
Fulcrum Therapeutics, Inc.'s stock currently trades at $3.75 with a market capitalization of $692.6M. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for Fulcrum Therapeutics, Inc.'s stock.
All SEC filings for Fulcrum Therapeutics, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View FULC Stock Page
Frequently Asked Questions
Where can I read FULC's SEC filings?
Browse all filings on our FULC SEC filings page.
What types of SEC filings does Fulcrum Therapeutics, Inc. file?
Public companies like Fulcrum Therapeutics, Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.